Loading…
Underlying
Underlying Price
$6.01
Type
Call
Strike
8
Expiration
Dec 11, 2026
DTE
28d
Moneyness
OTM
Intrinsic
$0.00
IBRX 8 Call Across Expirations
| Expiration | DTE | Last | Change | Vol | Open Int |
|---|---|---|---|---|---|
| Nov 13, 2026 | 0d | $0.75 | +0.00% | 10 | 1,521 |
| Nov 20, 2026 | 7d | $0.85 | -34.62% | 178 | 2,043 |
| Nov 27, 2026 | 14d | $1.13 | -19.29% | 11 | 63 |
| Dec 4, 2026 | 21d | $1.47 | +13.08% | 4 | 16 |
| Dec 11, 2026 | 28d | — | — | 0 | 0 |
| Dec 18, 2026 | 35d | $1.35 | -28.95% | 61 | 375 |
| Dec 24, 2026 | 41d | — | — | 0 | 28 |
| Dec 31, 2026 | 48d | — | — | 0 | 0 |
| Mar 19, 2027 | 126d | $2.10 | -9.87% | 3 | 2,006 |
| Apr 16, 2027 | 154d | $2.20 | +22.22% | 20 | 84 |
| May 21, 2027 | 189d | $2.25 | -31.82% | 2 | 63 |
IBRX Profile
immunitybio is a leading registration-stage immuno-oncology and infectious disease company activating both the innate (natural killer cell and macrophage) and adaptive (t cell) immune system. we are developing molecular and product platforms including n-803, aldoxorubicin, and a second-generation adenovirus vector, which are based upon our three key modalities of activating natural killer ('nk') and t cells, tumoricidal macrophages, and memory t cells.